Acromegaloid Facial Appearance Syndrome Overview
Learn About Acromegaloid Facial Appearance Syndrome
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Allegheny Endocrinology Associates PC
Murray Gordon is an Endocrinologist in Pittsburgh, Pennsylvania. Dr. Gordon is rated as an Elite provider by MediFind in the treatment of Acromegaloid Facial Appearance Syndrome. His top areas of expertise are Acromegaly, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaloid Facial Appearance Syndrome, Hormone Replacement Therapy (HRT), and Thyroidectomy.
Cedars-Sinai Pituitary Center
Shlomo Melmed is an Endocrinologist in Los Angeles, California. Dr. Melmed is rated as an Elite provider by MediFind in the treatment of Acromegaloid Facial Appearance Syndrome. His top areas of expertise are Acromegaly, Acromegaloid Facial Appearance Syndrome, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Pituitary Tumor, and Hormone Replacement Therapy (HRT).
CUIMC/Harkness Pavilion
Pamela Freda is an Oncologist in New York, New York. Dr. Freda is rated as an Elite provider by MediFind in the treatment of Acromegaloid Facial Appearance Syndrome. Her top areas of expertise are Acromegaly, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaloid Facial Appearance Syndrome, and Pituitary Tumor.
Summary: There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood. The gene(s) involved in the pathogenesis of these tumors are largely not known; their possible association with other developmental defects or inheritance pattern(s) has not been investigated. The present...
Summary: The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.